Loading...

JAGX JAGUAR HEALTH INC Company Mergers 8-K Filing

JGR

JGX

JAGUAR HEALTH INC

(JAGX)

2026 8-K

Royalty Agreement Update

Nasdaq Delisting Notice

Preferred Stock Dividend

Dividend Announcement

Royalty Interest Exchange

License Agreement Announced

Filing Amendment

Financial Agreement Update

Funding Agreement

Stock Exchange Agreement

Stockholder Meeting Results

Royalty Amendments Announced

Financing Agreement Signed

Equity Exchange Agreement

Securities Purchase Agreement

PIPE Financing Agreement

Annual Meeting Results

ATM Agreement Update

Equity Offerings

Debt Restructuring

Equity Offerings

Equity Offerings

Investor Meetings

Equity Offerings

Product Expansion

Investor Meetings

Debt Restructuring

Investor Meetings

Investor Presentation

Private Placement

Earnings Announcement

Securities Agreement

Stock Split Announcement

Stockholder Meeting

Dividend Declaration

ATM Agreement Amendment

Q3 Earnings Report

Q2 Earnings Report

FDA Trial Results

Amendment to Offering Agree...

Equity Issuance

Nasdaq Listing Compliance

Annual Meeting Results

Equity Issuance

Amendment to At the Market ...

Special Meeting Results

Securities Purchase and Exc...

Equity Disinvestment

Debt Extinguishment and Exc...

Lease Agreement Amendments

Amendments and Exchange Agr...

Earnings Reports

Management Changes

Amendment to Inducement Awa...

Earnings Reports

Private Placement

Earnings Reports

Nasdaq Listing Compliance

Termination of License Agre...

Reverse Stock Split

External Links:

On January 12, 2026, Jaguar Health, Inc. reported a License Agreement where their subsidiary Napo Pharmaceuticals licensed products to Woodward Specialty LLC, receiving an upfront payment of $18 million and potential milestone payments of up to $17 million.

AI Assistant

JAGUAR HEALTH INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.